医学
内科学
胃肠病学
淋巴瘤
细胞因子释放综合征
外科
耐火材料(行星科学)
化疗
存活率
临床研究阶段
嵌合抗原受体
免疫疗法
癌症
物理
天体生物学
作者
Weidong Han,Yao Wang,Yang Liu,Chuan Tong,Chunmeng Wang,Yelei Guo,Dongdong Ti,Qingming Yang,Shen Qiao,Zhiqiang Wu,Weidong Han
出处
期刊:Leukemia
[Springer Nature]
日期:2021-07-16
卷期号:36 (1): 189-196
被引量:66
标识
DOI:10.1038/s41375-021-01345-8
摘要
Abstract Increasing the remission rate and reducing the recurrence rate can improve the clinical efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non-Hodgkin lymphoma (r/rNHL). In this open-label, single-arm phase I/II trial, 87 patients with r/rNHL, including 58 patients with aggressive diffuse large B-cell lymphoma and 24 with high tumour burden, received an infusion at doses of 0.5 × 10 6 –8 × 10 6 TanCAR7 T cells per kilogram of body weight after conditioning chemotherapy. The best overall response rate was 78% (95% confidence interval [CI], 68–86); response rates were consistent across prognostic subgroups. The median follow-up was 27.7 months. The median progression-free survival was 27.6 months (95% CI, 11 to not reached). Cytokine release syndrome (CRS) occurred in 61 patients (70%) with 60% of cases being grade 1 or 2 and 10% being grade 3 or greater. Grade 3 CAR T cell-related encephalopathy syndrome (CRES) occurred in 2 patients (2%). Two patients died from treatment-associated severe pulmonary infection, and one died from CRS-related pulmonary injury between 1 and 3 months post infusion. Long-term remissions were observed following the use of TanCAR7 T cells in r/rNHL with a safety profile that included CRS but few cases of CRES.
科研通智能强力驱动
Strongly Powered by AbleSci AI